Liu Furong, Zeng Gucheng, Zhou Shaotang, He Xiaoshun, Sun Nianfeng, Zhu Xiaofeng, Hu Anbin
Sun Yat-Sen university, The First Affiliated Hospital, department of surgical intensive care unit, 510080 Guangzhou, China.
Sun Yat-Sen university, department of microbiology, Zhongshan School of Medicine, Guangzhou, China.
Bull Cancer. 2018 May;105(5):493-501. doi: 10.1016/j.bulcan.2018.01.018. Epub 2018 Mar 22.
The immunosuppression of tumor-infiltrating lymphocytes (TILs) is associated with rapid progression of hepatitis B virus-related hepatocellular carcinoma (HBV-HCC). T cell Ig- and mucin-domain-containing molecule-3 (Tim-3) and programmed cell death 1 (PD-1) are important inhibitory molecules expressed on the surface of T cells, but their roles in the function of TILs in HBV-HCC are poorly understood. We aimed to study the roles of these two markers in HBV-HCC.
Ninety patients with pathologically confirmed HBV-associated HCC were enrolled in our study. Blood samples, paired fresh tumor tissues and adjacent tissues were collected, and isolating peripheral blood mononuclear cells, TILs and adjacent-infiltrating lymphocytes were isolated from these samples. The patients were followed-up to allow survival analysis.
Tim-3 or/and PD-1 was up-regulated expressed on CD4 and CD8 TILs in HBV-HCC patients and a higher proportion of TILs expressed PD-1 alone. Tim-3 and PD-1 TILs greatly decreased secretion of IFN-? and TNF-a. Expression of Tim-3 and PD-1 on TILs negatively correlated with disease-free survival of HCC patients. Direct blockade of Tim-3 and PD-1 in vitro significantly enhanced TILs proliferation and secretion of IFN-? and TNF-a.
Expression of Tim-3 and/or PD-1 on TILs impairs their function and correlates negatively with disease-free survival in HBV-HCC. Direct blockade of Tim-3 and PD-1 restores anti-tumor effects of TILs, which suggests a potential target for novel immunotherapy in HBV-HCC.
肿瘤浸润淋巴细胞(TILs)的免疫抑制与乙型肝炎病毒相关肝细胞癌(HBV-HCC)的快速进展有关。含T细胞免疫球蛋白和粘蛋白结构域分子-3(Tim-3)和程序性细胞死亡蛋白1(PD-1)是T细胞表面表达的重要抑制分子,但它们在HBV-HCC中TILs功能中的作用尚不清楚。我们旨在研究这两种标志物在HBV-HCC中的作用。
90例经病理证实的HBV相关性肝癌患者纳入本研究。采集血液样本、配对的新鲜肿瘤组织和癌旁组织,并从这些样本中分离外周血单个核细胞、TILs和癌旁浸润淋巴细胞。对患者进行随访以进行生存分析。
Tim-3或/和PD-1在HBV-HCC患者的CD4和CD8 TILs上表达上调,且有更高比例的TILs单独表达PD-1。Tim-3和PD-1 TILs显著降低了IFN-γ和TNF-α的分泌。TILs上Tim-3和PD-1的表达与HCC患者的无病生存期呈负相关。体外直接阻断Tim-3和PD-1可显著增强TILs的增殖以及IFN-γ和TNF-α的分泌。
TILs上Tim-3和/或PD-1的表达损害其功能,并与HBV-HCC的无病生存期呈负相关。直接阻断Tim-3和PD-1可恢复TILs的抗肿瘤作用,这提示其可能是HBV-HCC新型免疫治疗的潜在靶点。